智通财经1月8日讯（记者 何凡）今日国内第七款注射用 A 型肉毒毒素产品获批上市，该A型肉毒毒素 100U产品由爱美客（300896.SZ）从韩国Huons BP引入。随着越来越多的玩家进入肉毒毒素赛道，爱美 客能否依靠上述产品缓解业绩下滑态势值得持续关注。 爱美客方面表示，本次注射用 A 型肉毒毒素产品药品注册证的获取是公司战略布局的关键里程碑，该 产品通过与现有产品的组合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞争力。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 今日晚间，爱美客公告称，公司在中国（包括澳门和香港）独家经销韩国Huons BP生产的注射用A型肉 毒毒素产品获得国家药监局核准签发的《药品注册证书》。 2022年5月20日，爱美客与Huons BP签订《经销协议》，公司以研发注册方式引进 Huons BP 生产的注 射用 A 型肉毒毒素产品，并在约定经销区域（指中国，包括澳门和香港）内作为 Huons ...

Group 1 - The core point of the article is that Fosun International is expanding its capital footprint by pushing its subsidiary, Shanghai Yiyao Technology Co., Ltd., towards an IPO in the A-share market, which would mark another addition to its portfolio of listed companies [1][3] - Fosun has developed into an innovative global family consumption industry group over more than 30 years, focusing on a happiness ecosystem centered around health, happiness, and wealth [1][4] - As of now, Fosun controls six A-share listed companies and four Hong Kong-listed companies, with four of the A-share companies having a market capitalization exceeding 10 billion [1][6] Group 2 - The financial performance of Fosun's listed companies shows significant divergence, with six companies reporting a decline in net profit, reflecting operational pressures in certain sectors [1][8] - In the first three quarters of 2025, among the six A-share companies, Shanghai Steel Union reported the highest revenue of approximately 57.32 billion, while the net profit of several companies, including Yuyuan and Hainan Mining, saw a year-on-year decline [8][9] - Fosun's strategic focus is shifting from diversified expansion to deepening its core sectors, particularly in health and intelligent manufacturing, as indicated by its efforts to optimize cash flow and enhance capital efficiency [7]

《CollaborationandLicenseAgreement》("许可协议")，其中主要包括由药友制药就口服小分子胰高血糖 素样肽-1受体(GLP-1R)激动剂(包括YP05002)及含有该活性成分的产品授予辉瑞于许可区域(即全球范围) 及领域(人类、动物所有适应症的治疗、诊断及预防)独家开发、使用、生产及商业化权利。截至目前， 药友制药已收到辉瑞支付的首付款15000万美元。 证券日报网讯1月8日，重药控股（000950）在互动平台回答投资者提问时表示，2025年12月9日，公司 参股子公司药友制药与上海复星医药（600196）产业发展有限公司及辉瑞共同签订 ...

Core Viewpoint - The antibacterial drug market in China is under pressure, with sales expected to drop below 100 billion yuan in 2024 and continue declining by approximately 18% in the first three quarters of 2025, reaching over 60 billion yuan [1][14]. Market Performance - The total sales of systemic antibacterial drugs in public medical institutions in China have been declining, with a significant drop in sales from 2024 to 2025 [1][14]. - The market for systemic antibacterial drugs includes 12 major therapeutic categories, with cephalosporins leading but experiencing four consecutive years of sales decline from 2022 to the first three quarters of 2025 [3][16]. Company Rankings - In the ranking of major companies, Pfizer, China National Pharmaceutical Group, and North China Pharmaceutical Group hold the top three positions, with sales exceeding 6.2 billion yuan, 2.1 billion yuan, and 1.9 billion yuan respectively in the first three quarters of 2025 [5][18]. - Nanjing Youke Biological, ranked fifteenth, showed remarkable growth with a year-on-year increase of 137.17%, marking its first entry into the top 20 groups [5][18]. Product Performance - The top 20 systemic antibacterial drugs accounted for over 50% of the market share, with the leading product, injectable cefoperazone/sulbactam (2:1), achieving sales of over 4.5 billion yuan [21][22]. - Notably, the compound injection of cefoperazone/sulbactam saw a dramatic increase of 219.32%, marking a significant rise in its market presence [21][23]. National Procurement Impact - Among the top 20 products, 15 have been included in the national procurement program, with 13 experiencing double-digit declines in sales [21][23]. - The tenth batch of national procurement saw injectable piperacillin/tazobactam drop by 55.61%, while the eleventh batch saw injectable cefoperazone/sulbactam decline by 47.56% [21][23]. New Drug Development - Currently, there are no domestic class 1 new drugs among the top 20 systemic antibacterial products, although five class 1 new antibacterial drugs have been approved since 2021 [25][26]. - Eight products meet the criteria for national procurement inclusion, with seven being injectable forms and one oral formulation [25][26].

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo, has submitted a drug registration application for a new drug targeting ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, which has been accepted by the National Medical Products Administration [1] Group 1 - The new drug is an innovative small molecule chemical drug [1] - The application is specifically for the treatment of patients with ALK-positive locally advanced or metastatic NSCLC [1] - Another indication for the drug, targeting ROS1-positive non-small cell lung cancer, has completed Phase II clinical trials in mainland China [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Fosun Wanguo, has submitted a drug registration application for a new drug, SAF-189, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] - The new drug is an innovative small molecule chemical drug, with another indication for ROS1-positive NSCLC having completed Phase II clinical trials in mainland China as of the announcement date [1] - As of November 2025, the cumulative R&D investment for this new drug is approximately RMB 480 million (unaudited) [1] Group 2 - According to IQVIA CHPA data, the sales revenue for major drugs treating ALK-positive NSCLC in mainland China is projected to be approximately RMB 3.367 billion in 2024 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for a new indication of a drug targeting ALK-positive non-small cell lung cancer, which has been accepted by the National Medical Products Administration [1] Group 1 - Fosun Pharma announced that its subsidiary Fosun Wanbang has received acceptance for a drug registration application for Dihydroartemisinin-Ruxolitinib capsules [1] - The application is specifically for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) [1]

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for a new drug, SAF-189, which targets ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients [1] Group 1 - The drug SAF-189 is classified as a Class 1 chemical drug [1] - The application has been accepted by the National Medical Products Administration of China [1] - The indication for the new drug is specifically for patients with ALK-positive locally advanced or metastatic NSCLC [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for SAF-189, a new drug aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - The drug registration application has been accepted by the National Medical Products Administration [1] - SAF-189 is classified as a Class 1 chemical drug [1] - The indication for this new drug is specifically for patients with ALK-positive NSCLC [1]